However, in the estimate, when deleting the study of Mao[27], we found that a new pooled significant HR = 1.63 (95%CI: 1.25–2.13, P = 0.0003), which supported the negetive prognostic value of SPARC expression in patients with pancreatic cancer, as compared with the old pooled HR with a P = 0.44. Here, SPARC is linked to familial pancreatic carcinoma.